[
    [
        {
            "time": "",
            "original_text": "药明康德在美国扩建的测试事业部基地正式投入运营",
            "features": {
                "keywords": [
                    "药明康德",
                    "美国",
                    "扩建",
                    "测试事业部",
                    "基地",
                    "投入运营"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "药明康德在美国扩建的测试事业部基地正式投入运营",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "药明康德：在美国新泽西州扩建研发基地 提升药物研发测试服务能力",
            "features": {
                "keywords": [
                    "药明康德",
                    "美国",
                    "新泽西州",
                    "扩建",
                    "研发基地",
                    "提升",
                    "服务能力"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "药明康德：在美国新泽西州扩建研发基地 提升药物研发测试服务能力",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "药明康德募资堪比抽水机的功率 这事该怎么看？",
            "features": {
                "keywords": [
                    "药明康德",
                    "募资",
                    "抽水机",
                    "功率"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "药明康德募资堪比抽水机的功率 这事该怎么看？",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "603259药明康德|新股药明康德申购详情",
            "features": {
                "keywords": [
                    "603259",
                    "药明康德",
                    "新股",
                    "申购"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "603259药明康德|新股药明康德申购详情",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 9,
                "Duration": 4,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "证券研究院|一文读懂“医药独角兽”药明康德招股意向书",
            "features": {
                "keywords": [
                    "证券研究院",
                    "医药独角兽",
                    "药明康德",
                    "招股意向书"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "证券研究院|一文读懂“医药独角兽”药明康德招股意向书",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "杜坤维:单纯限制IPO首募资金不是一个好方式",
            "features": {
                "keywords": [
                    "杜坤维",
                    "IPO",
                    "首募资金",
                    "限制",
                    "方式"
                ],
                "sentiment_score": -0.4,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "杜坤维:单纯限制IPO首募资金不是一个好方式",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        }
    ]
]